公开(公告)号：US20240350465A1

公开(公告)日：2024-10-24

申请号：US18294996

申请日：2021-08-04

申请人： UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE

发明人： David J. SCHNEIDER

IPC分类号： A61K31/4365 ,  A61K31/405 ,  A61K31/4433 ,  A61K31/519 ,  A61K31/616 ,  A61K45/06 ,  G01N15/14 ,  G01N33/68

CPC分类号： A61K31/4365 ,  A61K31/405 ,  A61K31/4433 ,  A61K31/519 ,  A61K31/616 ,  A61K45/06 ,  G01N15/14 ,  G01N33/6854

摘要： The present invention features methods for selecting treatment for a patient having suffered a minor stroke or transient ischemic attack (TIA) associated with intracranial atherosclerotic disease (ICAD).

公开(公告)号：US20240315974A1

公开(公告)日：2024-09-26

申请号：US18736621

申请日：2024-06-07

申请人： MATRIPHARM INTERNATIONAL INC.

发明人： Tien Canh LE ,  Mircea-Alexandru MATEESCU

IPC分类号： A61K9/20 ,  A61K31/192 ,  A61K31/405 ,  A61K31/616 ,  A61K45/06

CPC分类号： A61K9/2059 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K31/192 ,  A61K31/405 ,  A61K31/616 ,  A61K45/06

摘要： The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.

公开(公告)号：US20240270692A1

公开(公告)日：2024-08-15

申请号：US18433832

申请日：2024-02-06

申请人： TOHOKU UNIVERSITY

发明人： Takaaki ABE ,  Yotaro Matsumoto ,  Takehiro Suzuki ,  Ryota Kujirai ,  Atsushi Higashitani ,  Takeya Sato ,  Eunsang Kwon

IPC分类号： C07D209/18 ,  A61K31/405 ,  A61K47/02 ,  A61K47/10 ,  A61P27/16

CPC分类号： C07D209/18 ,  A61K31/405 ,  A61K47/02 ,  A61K47/10 ,  A61P27/16

摘要： An S(+) form of 4-(2,4-difluorophenyl)-2-(1H-indol-3-yl)-4-oxo-butanoic acid or a physiologically acceptable salt thereof may be useful as an active ingredient of a pharmaceutical composition or a food or drink composition, and the like. An enantiomeric excess of an S(+) form may be at least 97% or more. The compound may be used in treating, improving, or preventing a mitochondrial disease and/or a symptom or a disease associated with aging.

公开(公告)号：US12059427B2

公开(公告)日：2024-08-13

申请号：US16961198

申请日：2018-01-15

申请人： YINUOKE MEDICINE SCIENCE AND TECHNOLOGY COMPANY LTD.

发明人： Lingbing Zhang ,  Dongxu Zhang

IPC分类号： A61K31/7068 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61P21/06 ,  A61P35/00 ,  A61P37/06

CPC分类号： A61K31/7068 ,  A61K31/12 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/40 ,  A61K31/405 ,  A61K31/407 ,  A61P21/06 ,  A61P35/00 ,  A61P37/06

摘要： Provided are methods and compositions for treating cachexia in order to reduce the morbidity and mortality of chronic illnesses and to improve the effectiveness of treating chronic illness overall. More specifically, provided herein are methods and compositions for treating cachexia by agents that modulate the immune system and/or inflammation.

公开(公告)号：US20240261264A1

公开(公告)日：2024-08-08

申请号：US18537398

申请日：2023-12-12

申请人： Mayo Foundation for Medical Education and Research ,  The Regents of the University of California

发明人： Purna C. Kashyap ,  Michael Fischbach ,  Brianna B. Williams

IPC分类号： A61K31/405 ,  A61K35/00 ,  A61K35/74 ,  A61K35/741 ,  A61K35/742

CPC分类号： A61K31/405 ,  A61K35/74 ,  A61K35/741 ,  A61K35/742 ,  A61K2035/115 ,  Y02A50/30

摘要： This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and/or to treat gastrointestinal disorders are provided.

公开(公告)号：US20240245643A1

公开(公告)日：2024-07-25

申请号：US18473061

申请日：2023-09-22

申请人： The Institute of Cancer Research: Royal Cancer Hospital ,  Kudos Pharmaceuticals Limited

发明人： Alan Ashworth ,  Stephen Jackson ,  Niall Martin ,  Graeme Cameron Murray Smith

IPC分类号： A61K31/366 ,  A61K31/00 ,  A61K31/405 ,  A61K31/4184 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/502 ,  A61K31/517 ,  A61K31/522 ,  A61K31/675

CPC分类号： A61K31/366 ,  A61K31/00 ,  A61K31/405 ,  A61K31/4184 ,  A61K31/4706 ,  A61K31/473 ,  A61K31/502 ,  A61K31/517 ,  A61K31/522 ,  A61K31/675 ,  Y02A50/30

摘要： The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.

公开(公告)号：US12042514B2

公开(公告)日：2024-07-23

申请号：US18122478

申请日：2023-03-16

申请人： Tygrus, LLC

发明人： Paul Bundschuh ,  Lawrence Carlson ,  Shawn Dolan ,  Andrew M. Yaksic

IPC分类号： A61K33/42 ,  A61K9/00 ,  A61K31/137 ,  A61K31/198 ,  A61K31/215 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/4704 ,  A61K31/513 ,  A61K31/569 ,  A61K31/573 ,  A61K31/58 ,  A61K31/616 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00 ,  A61K33/04 ,  A61K33/20 ,  A61K33/40 ,  A61K45/06 ,  A61P31/04 ,  A61P31/10 ,  A61P31/14 ,  A61P31/16

CPC分类号： A61K33/42 ,  A61K9/0078 ,  A61K31/137 ,  A61K31/198 ,  A61K31/215 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/4704 ,  A61K31/513 ,  A61K31/569 ,  A61K31/573 ,  A61K31/58 ,  A61K31/616 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7076 ,  A61K33/00 ,  A61K33/04 ,  A61K33/20 ,  A61K33/40 ,  A61K45/06 ,  A61P31/04 ,  A61P31/10 ,  A61P31/14 ,  A61P31/16

摘要： Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

公开(公告)号：US20240180978A1

公开(公告)日：2024-06-06

申请号：US18279388

申请日：2022-02-28

申请人： EVONIK OPERATIONS GMBH

发明人： Bodo SPECKMANN ,  Michael SCHWARM ,  Michael SCHILLING

IPC分类号： A61K35/747 ,  A23L33/135 ,  A23L33/175 ,  A61K31/405 ,  C12N1/20 ,  C12R1/24 ,  C12R1/25

CPC分类号： A61K35/747 ,  A23L33/135 ,  A23L33/175 ,  A61K31/405 ,  C12N1/20 ,  C12R2001/24 ,  C12R2001/25

摘要： The current invention concerns preparations comprising probiotic strains belonging to the genus Lactobacillus in combination with the amino acid L-tryptophan.

公开(公告)号：US11998577B2

公开(公告)日：2024-06-04

申请号：US17682051

申请日：2022-02-28

申请人： ABBOTT LABORATORIES

发明人： Alejandro Barranco Perez ,  Maria Ramirez Gonzalez ,  Rachael Buck ,  Enrique Vazquez Hernandez

IPC分类号： A61K35/747 ,  A23L33/00 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14

CPC分类号： A61K35/747 ,  A23L33/125 ,  A23L33/135 ,  A23L33/15 ,  A23L33/40 ,  A61K9/107 ,  A61K31/015 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/14 ,  A61K31/145 ,  A61K31/205 ,  A61K31/355 ,  A61K31/405 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/702 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/714 ,  A61K33/06 ,  A61K33/26 ,  A61K33/30 ,  A61K35/20 ,  A61K35/745 ,  A61K47/02 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/36 ,  A61K47/42 ,  A61K47/44 ,  A61K47/46 ,  A61P1/14 ,  A23V2002/00

摘要： Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

公开(公告)号：US11986494B2

公开(公告)日：2024-05-21

申请号：US17120883

申请日：2020-12-14

申请人： University of Florida Research Foundation, Inc.

发明人： Sam Xianjun Cheng

IPC分类号： A61K33/30 ,  A23L33/00 ,  A61K9/00 ,  A61K9/08 ,  A61K31/132 ,  A61K31/405 ,  A61K33/00 ,  A61K33/06 ,  A61K33/10 ,  A61K45/06 ,  A61P1/12

CPC分类号： A61K33/30 ,  A23L33/40 ,  A61K9/0095 ,  A61K9/08 ,  A61K31/132 ,  A61K31/405 ,  A61K33/00 ,  A61K33/06 ,  A61K33/10 ,  A61K45/06 ,  A61P1/12 ,  A23V2002/00 ,  Y02A50/30 ,  A61K33/30 ,  A61K2300/00 ,  A61K33/06 ,  A61K2300/00 ,  A61K31/405 ,  A61K2300/00 ,  A61K31/132 ,  A61K2300/00 ,  A61K33/00 ,  A61K2300/00

摘要： The present invention pertains to the use of the calcium-sensing receptor (CaSR)-activating nutrients (designated as “CaSR-based nutrients”) for the prevention and/or treatment of diarrheal diseases and inflammation in the gastrointestinal tract. In one embodiment, the current invention is formulated for oral administration. The anti-diarrheal composition of the present invention is useful for treating diarrheal and gastrointestinal inflammatory conditions in infants and young children.